Pancreatic Cancer Research

ResearcherComprehensive Cancer Center ViennaNo recent work listed

Matthias Unseld

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1699-9846; OpenAlex author ID A5017933929. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers

Papers 9

  1. The HDL particle composition determines its antitumor activity in pancreatic cancer. Co-author DOI 10.26508/lsa.202101317↗
  2. Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. Last author DOI 10.7150/jca.70500↗
  3. Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing. Co-author DOI 10.2147/cmar.s308029↗
  4. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. First author DOI 10.3390/jcm9030648↗
  5. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. Co-author DOI 10.1016/j.tranon.2018.08.019↗
  6. A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid. First author DOI 10.1177/1758835919853196↗
  7. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chem… First author DOI 10.1007/s12032-018-1223-3↗
  8. Cross-over comparison and new chemotherapy regimens in metastatic pancreatic cancer. First author DOI 10.1007/s12254-017-0352-2↗
  9. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. Co-author DOI 10.1038/s41598-017-04743-0↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Markus Kieler · 8 shared papers, 2017–2022 · strength 0.91
  2. Daniela Bianconi · 8 shared papers, 2017–2022 · strength 0.91
  3. Gerald W. Prager · 8 shared papers, 2017–2022 · strength 0.91
  4. Werner Scheithauer · 3 shared papers, 2017–2020 · strength 0.31
  5. Berthold Streubel · 2 shared papers, 2017–2021 · strength 0.21
  6. J. Thaler · 1 shared paper, 2022 · strength 0.17
  7. Sukirthini Balendran · 1 shared paper, 2021 · strength 0.15
  8. Christoph Carl Zielinski · 2 shared papers, 2017–2019 · strength 0.15
  9. Martin Schindl · 1 shared paper, 2020 · strength 0.13
  10. Raimund Oberle · 1 shared paper, 2022 · strength 0.13
  11. Herbert Stangl · 1 shared paper, 2022 · strength 0.13
  12. Sonja Loges · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.